<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477319</url>
  </required_header>
  <id_info>
    <org_study_id>PROSPECT</org_study_id>
    <nct_id>NCT02477319</nct_id>
  </id_info>
  <brief_title>A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)</brief_title>
  <acronym>PROSPECT</acronym>
  <official_title>A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      identify and validate biomarkers that might reflect partial restoration of CFTR function and
      can be used to monitor disease progression, and ii) evaluate the mechanistic effects of CFTR
      modulators and other relevant therapies in individuals with CF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the
      cystic fibrosis transmembrane conductance regulator (CFTR) protein. Over 1,900 mutations,
      categorized into five genotypic or functional classes are implicated in causing CF. Severity
      of disease varies widely in CF based on CFTR-dependent and independent factors. Progressive
      obstructive lung disease is the main determinant of morbidity and mortality in CF; therefore
      it is critical to identify biomarker profiles that reflect and predict this phenotypic
      variability, and understand their relationship to residual CFTR activity. Emerging CFTR
      modulator therapies that directly target defective CFTR are being evaluated in pivotal
      clinical trials and may become available in the next few years. It is not known how partial
      restoration of CFTR function might impact CF disease progression and disease-related
      biomarkers. Thus there is urgent need to i) identify and validate biomarkers that might
      reflect partial restoration of CFTR function and can be used to monitor disease progression,
      and ii) evaluate the mechanistic effects of CFTR modulators and other relevant therapies in
      individuals with CF
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">April 25, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sweat Chloride by Cohort (Part A Only)</measure>
    <time_frame>For cohort 1, sweat chloride at Day 0 is time frame. For cohorts 2-3, sweat chloride averaged across all 3 visits at days 0, 14 and 90 is time frame.</time_frame>
    <description>This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic.
For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Month Change in FEV1 Percent Predicted (Part B Only)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>This is the primary endpoint for Part B per the PROSPECT protocol. Change in FEV1 Percent Predicted is only relevant for Part B as it captures changes in lung function post-initiation of Ivacaftor/Lumacaftor.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">452</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <description>Cohort 1: Healthy Controls
Cohort 2: Partial CFTR function CF (class IV/V)
Cohort 3: Absent CFTR function CF (Class I/II)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <description>CF patients who are homozygous for the F508del</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Part A N = 260 (210 CF, 50 non-CF controls)

          -  Cohort 1: 50 non-CF control subjects ≥ 12 years of age, with at least 15 subjects 12 -
             21 yrs of age

          -  Cohort 2: 50 Partial CFTR Function CF subjects with at least one class IV/V CFTR
             mutation, ≥ 12 years of age

          -  Cohort 3 160 Absent CFTR Function CF subjects with two class I/II mutations ≥ 12 years
             of age

        Part B

        Up to 250 CF subjects who are homozygous for F508del mutation and who are prescribed
        ivacaftor/lumacafor for clinical care will be allowed to enroll. This will include :

          -  Cohort 3 subjects homozygous for F508del mutation from Part A who are prescribed
             ivacaftor/lumacaftor will be invited to participate in Part B (up to 100 potential
             subjects).

          -  Up to 150 additional CF subjects homozygous for F508del mutation ≥ 12 years of age who
             did not participate in Part A but are otherwise eligible for participation in Part B.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Part A COHORT 1:

          -  1. Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative.

             2. Be willing and able to adhere to the study visit schedule and other protocol
             requirements 3. Male or female ≥ 12 years of age at Visit 1. 4. Have a body mass index
             (BMI) of:

               -  For subjects ≥ 18 years of age: ≤ 30 kg/m2

               -  For subjects 12 - 17 years of age: ≤ 95th percentile 5. Be a non-smoker for ≥ 1
                  year at screening and have ≤ 10 pack-year history of smoking.

                  6. To participate in the optional DNA banking component of this study, subject
                  must have signed the informed consent indicating willingness to participate in
                  the genomic component of the study. Refusal to give consent for this component
                  does not exclude a subject from participation in the study.

        Inclusion Cohorts 2-3

          1. Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative.

          2. Male or female ≥ 12 years of age at Visit 1.

          3. Documentation of a CF diagnosis as evidenced by one or more clinical features
             consistent with the CF phenotype and the following criteria: Cohort 2: (Partial
             Function CFTR CF)

               -  Two mutations in the CFTR gene:

                    -  At least one allele must be a Class IV or V mutation

                    -  The second allele can be within any CFTR mutation class.

               -  Pancreatic sufficient (based on the absence of daily PERT use)

               -  At least one historic sweat chloride ≥60 mEq/L by quantitative pilocarpine
                  iontophoresis test (QPIT) OR sweat chloride results ≥ 40, but &lt; 60mEQ/L upon
                  permission of the PROSPECT Investigator-Sponsors.

             Cohort 3: (Absent Function CF)

             • Two class I or II CFTR mutations

          4. Enrolled in the Cystic Fibrosis Foundation Patient Registry. Patients may enroll in
             the Registry at Visit 1 if not previously enrolled.

          5. Clinically stable with no significant changes in health status within 2 weeks prior to
             Visit 1.

          6. Be a non-smoker for ≥ 1 year at screening and have ≤ 10 pack-year history of smoking.

          7. To participate in the optional DNA banking component of this study, subject must have
             signed the informed consent indicating willingness to participate in the genomic
             component of the study. Refusal to give consent for this component does not exclude a
             subject from participation in the study

        Part B Inclusion

          1. Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative.

          2. Physician decision to treat with ivacaftor/lumacaftor.

          3. Completion of at least Visit 1 and Visit 2 of Part A

        Exclusion Criteria PART A COHORT 1

          1. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data.

          2. A history of any clinically significant medical illness or medical disorder that
             requires ongoing systemic medical therapy, including (but not limited to)
             cardiovascular disease, neuromuscular disease, hematological disease including
             bleeding disorders, chronic respiratory disease (including persistent asthma), hepatic
             or gastrointestinal (GI) disease, neurological disease, neoplastic disease, renal
             diseases, or endocrine disorders including diabetes.

          3. Acute illness requiring any new prescription or over-the-counter treatment within 14
             days prior to Visit 1.

          4. Major or traumatic surgery within 12 weeks prior to Visit 1.

          5. For females of child-bearing potential: a positive pregnancy test at Visit 1.

          6. Initiation of any new chronic therapy within 28 days prior to Visit 1.

          7. Use of an investigational agent within 28 days prior to Visit 1.

        Exclusion Part A COHORTS 2-3

          1. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data.

          2. Initiation of newly prescribed antibiotics [oral, intravenous (IV), and/or inhaled]
             for acute respiratory symptoms within 2 weeks of Visit 1.

          3. Major or traumatic surgery within 12 weeks prior to Visit 1.

          4. For females of child-bearing potential: a positive pregnancy test at Visit 1.

          5. Initiation of any new chronic therapy (e.g., ibuprofen Pulmozyme®, hypertonic saline,
             azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 1.

          6. Use of an investigational agent within 28 days prior to Visit 1.

          7. Use of oral corticosteroids in doses exceeding 10 mg prednisone/day or 20 mg
             prednisone/every other day (subjects on oral steroids will be on stable doses for &gt; 12
             weeks prior to visit 1).

          8. Active treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two
             antibiotics (oral, IV, and/or inhaled).

          9. Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to
             Visit 1.

         10. History of lung or liver transplantation, or listing for organ transplantation.

        Exclusion PART B

          1. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data.

          2. Initiation of newly prescribed antibiotics [oral, intravenous (IV), and/or inhaled]
             for acute respiratory symptoms within 2 weeks of Visit 4.

          3. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline,
             azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 4.

          4. Use of an investigational agent within 28 days prior to Visit 4.

          5. Use of oral corticosteroids in doses exceeding 10 mg prednisone/day or 20 mg
             prednisone/every other day (subjects on oral steroids will be on stable doses for &gt; 12
             weeks prior to Visit 4).

          6. Active treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two
             antibiotics (oral, IV, and/or inhaled).

          7. Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to
             Visit 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile S. Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Colarado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis University Hospital; James Whitcomb Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devon Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Fareri Children's Hospital; Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nation Wide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center; Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-9500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98145-9807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <results_first_submitted>April 7, 2020</results_first_submitted>
  <results_first_submitted_qc>May 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2020</results_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Steven M Rowe</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02477319/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02477319/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment Period: March 2015 - June 2017 (revised)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A (Cohort 1)</title>
          <description>• Cohort 1: Healthy Controls
Observational</description>
        </group>
        <group group_id="P2">
          <title>Part A (Cohort 2)</title>
          <description>Cohort 2: Partial CFTR function CF (class IV/V)
Observational</description>
        </group>
        <group group_id="P3">
          <title>Part A (Cohort 3)</title>
          <description>Cohort 3: Absent CFTR function CF (Class I/II)
Observational</description>
        </group>
        <group group_id="P4">
          <title>Part B</title>
          <description>F508del homozygous CF patients who initiated Lumacaftor/Ivacaftor
Observational (pre/post study)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="149"/>
                <participants group_id="P4" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A (Cohort 1)</title>
          <description>• Cohort 1: Healthy Controls
Observational</description>
        </group>
        <group group_id="B2">
          <title>Part A (Cohort 2)</title>
          <description>• Cohort 2: Partial CFTR function (CF class IV/V)
Observational</description>
        </group>
        <group group_id="B3">
          <title>Part A (Cohort 3)</title>
          <description>• Cohort 3: Absent CFTR function (CF Class I/II)</description>
        </group>
        <group group_id="B4">
          <title>Part B</title>
          <description>F508del homozygous CF patients who initiated Lumacaftor/Ivacaftor
Observational (pre/post study)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="164"/>
            <count group_id="B4" value="193"/>
            <count group_id="B5" value="452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="164"/>
                    <count group_id="B4" value="193"/>
                    <count group_id="B5" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="10.1"/>
                    <measurement group_id="B2" value="32.3" spread="18.1"/>
                    <measurement group_id="B3" value="21.8" spread="9.6"/>
                    <measurement group_id="B4" value="19.0" spread="10.6"/>
                    <measurement group_id="B5" value="22.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age Category</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="164"/>
                    <count group_id="B4" value="193"/>
                    <count group_id="B5" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&gt;=6 - 11 Y</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 12 - 17</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 18 - 29</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="164"/>
                    <count group_id="B4" value="193"/>
                    <count group_id="B5" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="164"/>
                    <count group_id="B4" value="193"/>
                    <count group_id="B5" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="189"/>
                    <measurement group_id="B5" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 % Predicted</title>
          <description>FEV1 % Predicted based on Global Lung Initiative (GLI) equations</description>
          <population>Cohort 1 participants did not perform spirometry procedures (i.e. are missing baseline FEV1 % Predicted). Also, one Cohort 2 participant is missing baseline spirometry.</population>
          <units>% Predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="164"/>
                    <count group_id="B4" value="193"/>
                    <count group_id="B5" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="86.9" spread="24.6"/>
                    <measurement group_id="B3" value="81.8" spread="23.4"/>
                    <measurement group_id="B4" value="85.0" spread="22.4"/>
                    <measurement group_id="B5" value="83.9" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sweat Chloride by Cohort (Part A Only)</title>
        <description>This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic.
For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model.</description>
        <time_frame>For cohort 1, sweat chloride at Day 0 is time frame. For cohorts 2-3, sweat chloride averaged across all 3 visits at days 0, 14 and 90 is time frame.</time_frame>
        <population>Participants with Sweat Chloride measure. For Cohort 1, sweat chloride was collected at Visit 1 only (Day 0). Cohort 2 and 3 were collected at Days 0, 14 and 90.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A (Cohort 1)</title>
            <description>Cohort 1: Healthy Controls Observational</description>
          </group>
          <group group_id="O2">
            <title>Part A (Cohort 2)</title>
            <description>Cohort 2: Partial CFTR function (CF class IV/V)</description>
          </group>
          <group group_id="O3">
            <title>Part A (Cohort 3)</title>
            <description>Cohort 3: Absent CFTR function (CF class I/II)</description>
          </group>
        </group_list>
        <measure>
          <title>Sweat Chloride by Cohort (Part A Only)</title>
          <description>This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic.
For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model.</description>
          <population>Participants with Sweat Chloride measure. For Cohort 1, sweat chloride was collected at Visit 1 only (Day 0). Cohort 2 and 3 were collected at Days 0, 14 and 90.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="19.2" upper_limit="24.7"/>
                    <measurement group_id="O2" value="81.0" lower_limit="74.3" upper_limit="87.7"/>
                    <measurement group_id="O3" value="101.4" lower_limit="100.1" upper_limit="102.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Month Change in FEV1 Percent Predicted (Part B Only)</title>
        <description>This is the primary endpoint for Part B per the PROSPECT protocol. Change in FEV1 Percent Predicted is only relevant for Part B as it captures changes in lung function post-initiation of Ivacaftor/Lumacaftor.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Change in FEV1 % predicted was measured in all participants who had baseline visit and 6 month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B</title>
            <description>Participants who initiated Ivacaftor/Lumacaftor</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Change in FEV1 Percent Predicted (Part B Only)</title>
          <description>This is the primary endpoint for Part B per the PROSPECT protocol. Change in FEV1 Percent Predicted is only relevant for Part B as it captures changes in lung function post-initiation of Ivacaftor/Lumacaftor.</description>
          <population>Change in FEV1 % predicted was measured in all participants who had baseline visit and 6 month visit.</population>
          <units>Percent Predicted</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.7" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>[Not Specified]</time_frame>
      <desc>This was an observational study. Adverse events were not an endpoint.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Arms/Groups</title>
          <description>Adverse Events were not analyzed by Arm/Group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Umer Khan (Principal Biostatistician)</name_or_title>
      <organization>Seattle Children's Hospital</organization>
      <phone>206-884-7516</phone>
      <email>umer.khan@seattlechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

